Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial

BACKGROUND: Neoadjuvant chemotherapies have been widely recommended in patients with locally advanced gastric cancer (LAGC). However, the evidence of combining neoadjuvant chemotherapy with anti–programmed death 1 (anti–PD-1) antibody therapy for patients with LAGC is lacking. Thus, we conducted a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Honghai, Ding, Ping’an, Sun, Chenyu, Yang, Peigang, Tian, Yuan, Liu, Yang, Lowe, Scott, Bentley, Rachel, Li, Yaru, Zhang, Zhidong, Wang, Dong, Li, Yong, Zhao, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458882/
https://www.ncbi.nlm.nih.gov/pubmed/36091139
http://dx.doi.org/10.3389/fonc.2022.927781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458882/
https://www.ncbi.nlm.nih.gov/pubmed/36091139
http://dx.doi.org/10.3389/fonc.2022.927781

Ejemplares similares